home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2454.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
42 lines
Document 2454
DOCN M94A2454
TI HIV seroincidence among injection drug users in Los Angeles, USA,
1989-1994.
DT 9412
AU Kerndt PR; Weber MD; Ford WL; Cheng FK; Lehman JS; HIV Epidemiology
Program, Los Angeles, CA.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):300 (abstract no. PC0128). Unique
Identifier : AIDSLINE ICA10/94370121
AB OBJECTIVE: To estimate HIV seroincidence (SI) and characterize risk
behaviors among injection drug users (IDUs) seeking methadone treatment
in Los Angeles County. METHODS: Records were reviewed at 3 methadone
treatment clinics to identify all clients who had more than one
confidential HIV test. Enrollment varied by clinic (3/89, 6/92, and
11/92, respectively) and is ongoing. Only clients whose first HIV test
was negative were included in the analysis. SI was calculated as the
number of seroconversions per 100 person years. RESULTS: Of the 2086
persons in treatment during the study period, 543 (26%) had two or more
HIV tests. Overall, HIV seroprevalence was 1.2% (26/2086). Among the 543
clients with repeat HIV tests, 337 (62%) were male, and 206 (38%) were
female; 265 (49%) were hispanic, were 261 (48%) white, and 17 were (3%)
black. Four hundred and eleven (79%) reported continued drug injection,
437 (87%) reported needle sharing in the past 12 months, while 434 (80%)
reported usually using bleach to clean needles/syringes prior to use.
One seroconversion was identified for a SI rate of 0.12 per 100 person
years. Results will be updated to include another year of follow-up.
CONCLUSIONS: The low SI is consistent with the low observed HIV
prevalence. The measured SI is likely to be a minimum estimate because
1) IDUs who do not remain in treatment or who do not return to treatment
may be at higher risk of infection, 2) blacks were undersampled, and 3)
recruitment was limited geographically. However, risk behaviors are
highly prevalent suggesting that rapid spread of HIV could occur should
seroprevalence rates increase. Ongoing drug treatment and behavioral
interventions along with continued surveillance for new infections is
necessary to monitor and control the spread of HIV among IDUs.
DE Female Human *HIV Seroprevalence Los Angeles/EPIDEMIOLOGY Male Risk
Factors Substance Abuse, Intravenous/*COMPLICATIONS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).